| Chapter title |
EBNA2 and Its Coactivator EBNA-LP.
|
|---|---|
| Chapter number | 2 |
| Book title |
Epstein Barr Virus Volume 2
|
| Published in |
Current topics in microbiology and immunology, January 2015
|
| DOI | 10.1007/978-3-319-22834-1_2 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-922833-4, 978-3-31-922834-1
|
| Authors |
Kempkes, Bettina, Ling, Paul D, Bettina Kempkes, Paul D. Ling |
| Abstract |
While all herpesviruses can switch between lytic and latent life cycle, which are both driven by specific transcription programs, a unique feature of latent EBV infection is the expression of several distinct and well-defined viral latent transcription programs called latency I, II, and III. Growth transformation of B-cells by EBV in vitro is based on the concerted action of Epstein-Barr virus nuclear antigens (EBNAs) and latent membrane proteins(LMPs). EBV growth-transformed B-cells express a viral transcriptional program, termed latency III, which is characterized by the coexpression of EBNA2 and EBNA-LP with EBNA1, EBNA3A, -3B, and -3C as well as LMP1, LMP2A, and LMP2B. The focus of this review will be to discuss the current understanding of how two of these proteins, EBNA2 and EBNA-LP, contribute to EBV-mediated B-cell growth transformation. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 39 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 15% |
| Student > Master | 5 | 13% |
| Student > Postgraduate | 4 | 10% |
| Student > Bachelor | 4 | 10% |
| Other | 2 | 5% |
| Other | 4 | 10% |
| Unknown | 14 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 11 | 28% |
| Agricultural and Biological Sciences | 5 | 13% |
| Immunology and Microbiology | 3 | 8% |
| Medicine and Dentistry | 2 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Other | 2 | 5% |
| Unknown | 15 | 38% |